CORDIS
EU research results

CORDIS

English EN
Development of influenza delNS1 virus as a vector for foreign antigens

Development of influenza delNS1 virus as a vector for foreign antigens

Objective

This project targets at combating diseases such as influenza and SARS. We propose to develop the influenza delNSl virus as a vector for antigens of foreign pathogens such as the SARS-associated coronavirus (SARS-CoV) and influenza virus. Candidate vaccines expressing SARS-CoV antigens as well as candidate vaccines expressing influenza virus antigens will be developed and tested in phase I clinical trials.

An important feature of the delNSl vector is, that deleting the pathogenicity factor NS1 not only leads to an attenuated phenotype but also results in stimulating an efficient immune response in the host. These are highly advantageous properties for a vaccine vector. In the case of the chimeric influenza delNS 1 vaccine, expressing antigens from different influenza types by the delNSl vector would eliminate the current need to combine three different influenza virus strains for vaccination. Therefore, production and purification costs will be significantly reduced, resulting in a cheaper vaccine.

The complementary constellation, the quality of the partners, efficient project management and availability of the combined resources will enable to successfully reach the goals of this project. It will allow the SMEs to significantly shorten the time necessary for the preclinical development phase and will bring the proposed chimeric vaccine viruses a major step closer to a marketable stage. Therefore, the project will contribute to the integration of partners in European research networks and, by its highly innovative features strengthen the European research.

Through the involvement of partners from the Czech republic and from Slovenia this project contributes to the integration of future member countries. Due to the enormous market potential, significant earnings can be expected. The patents, virus strains and technologies generated through these project will allow the SMEs to negotiate significant upfront, licensing and royalties payments from pharmaceuticals companies.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

GREEN HILLS BIOTECHNOLOGIY RESEARCH DEVELOPMENT TRADE GMBH

Address

Gersthofer StraSSE 29-31
Vienna

Austria

Administrative Contact

Andreas GRASSAUER (Dr)

Participants (6)

Sort alphabetically

Expand all

EMERGENTEC BUSINESS ANALYTICS GMBH

Austria

BIOTEST S.R.O.

Czechia

BIA SEPARATIONS D.O.O.

Slovenia

INSTITUTE OF INFLUENZA RUSSIAN ACADEMY OF MEDICAL SCIENCES

Russia

KLINIKUM DER JOHANN WOLFGANG GOETHE UNIVERSITÄT

Germany

MEDIZINISCHE UNIVERSITÄT WIEN

Austria

Project information

Grant agreement ID: 512864

  • Start date

    1 November 2004

  • End date

    30 April 2007

Funded under:

FP6-SME

  • Overall budget:

    € 1 917 945

  • EU contribution

    € 1 384 945

Coordinated by:

GREEN HILLS BIOTECHNOLOGIY RESEARCH DEVELOPMENT TRADE GMBH

Austria